Who are Tedizolid Phophate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azithromycin 1 gram IV, AzaSite Eye Drops, Azithromycin 3 days, Azithromycin and amoxicillin, Clindamycin Topical Gel 1%, Zmax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tedizolid-phophate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tedizolid Phophate — Competitive Intelligence Brief

Tedizolid Phophate (Tedizolid Phophate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oxazolidinone antibiotic. Area: Infectious Diseases.

phase 3 oxazolidinone antibiotic 50S ribosomal subunit Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Tedizolid Phophate (Tedizolid Phophate) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tedizolid Phophate TARGET	Tedizolid Phophate	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	oxazolidinone antibiotic	50S ribosomal subunit
Azithromycin 1 gram IV	Azithromycin 1 gram IV	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
AzaSite Eye Drops	AzaSite Eye Drops	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 3 days	Azithromycin 3 days	University of Oxford	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
Clindamycin Topical Gel 1%	Clindamycin Topical Gel 1%	Jinnah Postgraduate Medical Centre	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Zmax	Zmax	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oxazolidinone antibiotic class)

Bayer · 1 drug in this class
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tedizolid Phophate — Competitive Intelligence Brief. https://druglandscape.com/ci/tedizolid-phophate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab